PainReform (NASDAQ:PRFX) Stock Price Up 1.9% – Here’s What Happened

PainReform Ltd. (NASDAQ:PRFX)’s share price traded up 1.9% during trading on Tuesday . The stock traded as high as $2.73 and last traded at $2.67. 22,615 shares traded hands during trading, a decline of 96% from the average session volume of 638,700 shares. The stock had previously closed at $2.62.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, PainReform has a consensus rating of “Sell”.

PainReform Price Performance

The firm has a market capitalization of $1.07 million, a price-to-earnings ratio of 0.00 and a beta of 0.55. The business’s 50 day moving average price is $3.49 and its 200-day moving average price is $5.04.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.